(Q46671250)
English
A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the Cancer and Osteoporosis Research with Alendronate and
scientific article published on 11 September 2012
Statements
1 reference
A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the Cancer and Osteoporosis Research with Alendronate and (English)
1 reference
Laurence H Klotz
1 reference
Irene Y McNeill
1 reference
Marlene Kebabdjian
1 reference
Liying Zhang
1 reference
Joseph L Chin
1 reference
Canadian Urology Research Consortium
1 reference
11 September 2012
1 reference
1 reference
63
1 reference
5
1 reference
927-935
1 reference